Blurbs

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLYResearch Report) and Alnylam Pharma (ALNYResearch Report).

Eli Lilly & Co (LLY)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $396.00. The company’s shares closed last Monday at $323.40, close to its 52-week high of $341.70.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 4.9% and a 45.8% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Merck & Company.

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $371.56, representing a 14.0% upside. In a report issued on September 29, Bank of America Securities also maintained a Buy rating on the stock with a $390.00 price target.

See today’s best-performing stocks on TipRanks >>

Alnylam Pharma (ALNY)

In a report released today, Gary Nachman from BMO Capital maintained a Hold rating on Alnylam Pharma, with a price target of $200.00. The company’s shares closed last Monday at $200.16.

According to TipRanks.com, Nachman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 36.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Bausch Health Companies, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $236.68 average price target, which is a 15.4% upside from current levels. In a report released today, Berenberg Bank also maintained a Hold rating on the stock with a $184.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LLY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos